MoonLake Immunotherapeuti... (MLTX)
MoonLake Immunotherapeutics Statistics
Share Statistics
MoonLake Immunotherapeutics has 63.28M shares outstanding. The number of shares has increased by 0.65% in one year.
Shares Outstanding | 63.28M |
Shares Change (YoY) | 0.65% |
Shares Change (QoQ) | 0.35% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 52.78M |
Failed to Deliver (FTD) Shares | 15.32K |
FTD / Avg. Volume | 3.51% |
Short Selling Information
The latest short interest is 7.8M, so 12.37% of the outstanding shares have been sold short.
Short Interest | 7.8M |
Short % of Shares Out | 12.37% |
Short % of Float | 14.8% |
Short Ratio (days to cover) | 22.54 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -17.94. MoonLake Immunotherapeutics's PEG ratio is undefined.
PE Ratio | undefined |
Forward PE | -17.94 |
PS Ratio | 0 |
Forward PS | 1.9 |
PB Ratio | 0.01 |
P/FCF Ratio | undefined |
PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.11, with a Debt / Equity ratio of undefined.
Current Ratio | 21.11 |
Quick Ratio | 21.11 |
Debt / Equity | undefined |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | -41203.32 |
Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -0.27% and return on capital (ROIC) is 0%.
Return on Equity (ROE) | -0.27% |
Return on Assets (ROA) | -0.25% |
Return on Capital (ROIC) | 0% |
Revenue Per Employee | $0 |
Profits Per Employee | $-1,206,800,020 |
Employee Count | 100 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -282.2M |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.69% in the last 52 weeks. The beta is 1.3, so MoonLake Immunotherapeutics's price volatility has been higher than the market average.
Beta | 1.3 |
52-Week Price Change | -19.69% |
50-Day Moving Average | 42.09 |
200-Day Moving Average | 46.71 |
Relative Strength Index (RSI) | 44.26 |
Average Volume (20 Days) | 436.1K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | 0 |
Net Income | -120.68B |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -1919.51 |
Balance Sheet
The company has 180.43M in cash and 2.83M in debt, giving a net cash position of 177.6M.
Cash & Cash Equivalents | 180.43M |
Total Debt | 2.83M |
Net Cash | 177.6M |
Retained Earnings | -235.59B |
Total Assets | 477.93B |
Working Capital | 451.82B |
Cash Flow
In the last 12 months, operating cash flow was -116.59B and capital expenditures -519.52K, giving a free cash flow of -117.11B.
Operating Cash Flow | -116.59B |
Capital Expenditures | -519.52K |
Free Cash Flow | -117.11B |
FCF Per Share | -1862.67 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
MLTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -4918.04% |
FCF Yield | -4741.31% |
Analyst Forecast
The average price target for MLTX is $73, which is 87% higher than the current price. The consensus rating is "Buy".
Price Target | $73 |
Price Target Difference | 87% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Scores
Altman Z-Score | 0.5 |
Piotroski F-Score | 0 |